Capricor's Deramiocel Faces FDA Hurdles Despite Positive HOPE-3 Data — Capricor Therapeutics, Inc.

Event summary

Deramiocel's BLA under active FDA review after advisory committee voted 3-9 against its efficacy for cardiomyopathy in DMD.
HOPE-3 Phase 3 results published in The Lancet showed statistically significant improvement in upper limb function (p=0.029).
Capricor reported $238M in cash reserves as of June 30, 2026, down from $318M at year-end 2025.
Company withdrew preliminary injunction motion against NS Pharma to await FDA decision on Deramiocel.

The big picture

Capricor's struggle with FDA approval for Deramiocel highlights the challenges biotech companies face in navigating regulatory pathways for rare disease treatments. The company's focus on upper limb function, despite initial indications targeting cardiomyopathy, reflects broader industry trends of adapting clinical endpoints to demonstrate efficacy. With $238M in cash reserves, Capricor has financial flexibility but must balance aggressive commercialization plans with the uncertainty surrounding Deramiocel's regulatory fate.

What we're watching

Regulatory Pathway: Whether Capricor can secure FDA approval despite the unfavorable advisory committee vote and focus on upper limb function rather than cardiomyopathy.
Financial Runway: The pace at which Capricor burns through its $238M cash reserves while awaiting regulatory clarity for Deramiocel.
Commercial Strategy: How the delayed commercial readiness and potential arbitration with NS Pharma could impact Deramiocel's market launch timeline.